Patent US5071839A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5071839A Expired / Lapsed US ⏱️ 0.0 years remaining

Safe pharmaceutical composition for decreasing side effects of antiviral drugs and increasing the immune function (SDI) II

Assignee: Individual
•
Filing: 1987-11-02
•
Granted: 1991-12-10
•
Expires: 2007-11-02
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The new safe pharmaceutical composition (SDI II) and processes are provided for decreasing side effects of antiviral drugs and increasing the immune function. The pharmaceutical composition is composed of two ingredients: Polysaccharides of Wang Qi and Ginsenoside. The SDI II is nontoxic.

Inventors

  • 👤 Yaguang Liu

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-09 05:40
CPC Classifications
A; A61; A61K; A61K36/00; A61K36/18; A61K36/185; A61K36/25; A61K36/258; A61K31/00; A61K31/70; A61K31/7028; A61K31/7034; A61K31/704; A61K31/715; A61K36/48; A61K36/481

Claims Analysis

Total Claims: 3
Claim 1
Independent Claim 61 words
A pharmaceutical composition for decreasing side effects of anti-viral drugs comprising: 20-80 wt. % of polysaccharide of Wang Qi derived from a plant selected from the group consisting of Astragalus membranceus Bge, and Astragalus chrysopterus Bge; and 20-80 wt. % of ginsenoside derived from a plant selected from the group consisting of Panax quinquefolium L and Panax ginseng C. A. Mey.
Claim 2
Dependent Claim 61 words
A pharmaceutical composition for decreasing side effects of anti-viral drugs comprising: 20-80 wt. % of polysaccharide of Wang Qi derived from a plant selected from the group consisting of Astragalus membranceus Bge, and Astragalus chrysopterus Bge; and 20-80 wt. % of ginsenoside derived from a plant selected from the group consisting of Panax quinquefolium L and Panax ginseng C. A. Mey.
Claim 3
Dependent Claim 28 words
A method of reducing side effects of anti-viral drugs in humans suffering thereof comprising: administering to said humans an effective dosage of the pharmaceutical composition of claim 1.

References Cited (Backward Citations)

US4684628A Cited
US4675318A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1994-12-09 1995-06-10 1995-12-10 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1998-12-09 1999-06-10 1999-12-10 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2002-12-09 2003-06-10 2003-12-10 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag